淋巴瘤凝血异常机制及预后评估作用

doi:10.3760/cma.j.cn371439-20200318-00094

摘要/Abstract

摘要：

淋巴瘤是最常见的血液系统恶性肿瘤,常伴有凝血系统的异常。凝血系统的异常常导致血栓栓塞及出血等并发症,极大地增加了淋巴瘤患者死亡率。淋巴瘤患者凝血系统异常的机制主要包括肿瘤细胞分泌促凝因子的直接促凝机制及肿瘤细胞激活宿主细胞促凝潜力的间接促凝机制。淋巴瘤患者凝血功能相关因子的改变可能与淋巴瘤预后相关。

关键词: 淋巴瘤, 血液凝固障碍, 预后, 机制

Abstract:

Lymphoma is the most common hematological malignancy, often accompanied by coagulation abnormalities. Coagulative dysfunction leads to thromboembolic and bleeding complications, which greatly increases mortality in patients with lymphoma. The mechanisms of abnormal coagulation system in lymphoma mainly include the direct coagulation mechanism of tumor cells secreting procoagulant factors and the indirect coagulation mechanism of tumor cells activating the procoagulant potential of host cells. Coagulative factors may be related to the prognosis of lymphoma.

Key words: Lymphoma, Blood coagulation disorders, Prognosis, Mechanism

柴玥, 董梅. 淋巴瘤凝血异常机制及预后评估作用[J]. 国际肿瘤学杂志, 2020, 47(10): 637-640.

Chai Yue, Dong Mei. Prognostic role and mechanisms of abnormal coagulation system in lymphoma[J]. Journal of International Oncology, 2020, 47(10): 637-640.

参考文献 34

[1]	Sanfilippo KM, Wang TF, Gage BF, et al. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma[J]. Thromb Res, 2016,143:86-90. DOI: 10.1016/j.thromres.2016.05.008. doi: 10.1016/j.thromres.2016.05.008 pmid: 27208462
[2]	Hohaus S, Tisi MC, Bartolomei F, et al. Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization[J]. Blood Cancer J, 2018,8(6):54. DOI: 10.1038/s41408-018-0096-1. doi: 10.1038/s41408-018-0096-1 pmid: 29884791
[3]	Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis[J]. Cytometry A, 2016,89(2):111-122. DOI: 10.1002/cyto.a.22647. doi: 10.1002/cyto.a.22647 pmid: 25704723
[4]	Ball S, Nugent K. Microparticles in hematological malignancies: role in coagulopathy and tumor pathogenesis[J]. Am J Med Sci, 2018,355(3):207-214. DOI: 10.1016/j.amjms.2017.11.014. doi: 10.1016/j.amjms.2017.11.014 pmid: 29549921
[5]	Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis[J]. Semin Thromb Hemost, 2019,45(4):385-395. DOI: 10.1055/s-0039-1687894. doi: 10.1055/s-0039-1687894 pmid: 31096306
[6]	Xia Q, Zhang X, Chen Q, et al. Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer[J]. J Cancer, 2020,11(5):1195-1202. DOI: 10.7150/jca.37321. doi: 10.7150/jca.37321 pmid: 31956365
[7]	Han X, Guo B, Li Y, et al. Tissue factor in tumor microenvironment: a systematic review[J]. J Hematol Oncol, 2014,7:54. DOI: 10.1186/s13045-014-0054-8. doi: 10.1186/s13045-014-0054-8 pmid: 25084809
[8]	Chi S, Ikezoe T. Disseminated intravascular coagulation in non-Hodgkin lymphoma[J]. Int J Hematol, 2015,102(4):413-419. DOI: 10.1007/s12185-015-1854-5. doi: 10.1007/s12185-015-1854-5 pmid: 26272605
[9]	Falanga A, Russo L, Milesi V, et al. Mechanisms and risk factors of thrombosis in cancer[J]. Crit Rev Oncol Hematol, 2017,118:79-83. DOI: 10.1016/j.critrevonc.2017.08.003. doi: 10.1016/j.critrevonc.2017.08.003 pmid: 28917273
[10]	Vlodavsky I, Singh P, Boyango I, et al. Heparanase: from basic research to therapeutic applications in cancer and inflammation[J]. Drug Resist Updat, 2016,29:54-75. DOI: 10.1016/j.drup.2016.10.001. doi: 10.1016/j.drup.2016.10.001 pmid: 27912844
[11]	Lupu-Meiri M, Geras-Raaka E, Lupu R, et al. Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells[J]. J Cell Physiol, 2012,227(11):3621-3628. DOI: 10.1002/jcp.24068. doi: 10.1002/jcp.24068
[12]	Chen N, Ren M, Li R, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma[J]. Mol Cancer, 2015,14:140. DOI: 10.1186/s12943-015-0418-x. doi: 10.1186/s12943-015-0418-x pmid: 26215730
[13]	Reitter EM, Ay C, Kaider A, et al. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients[J]. Clin Exp Immunol, 2014,177(1):253-260. DOI: 10.1111/cei.12308. doi: 10.1111/cei.12308
[14]	Lee EC, Cameron SJ. Cancer and thrombotic risk: the platelet paradigm[J]. Front Cardiovasc Med, 2017,4:67. DOI: 10.3389/fcvm.2017.00067. doi: 10.3389/fcvm.2017.00067 pmid: 29164134
[15]	Grilz E, Marosi C, Königsbrügge O, et al. Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer[J]. J Thromb Haemost, 2019,17(8):1335-1344. DOI: 10.1111/jth.14484. doi: 10.1111/jth.14484 pmid: 31099477
[16]	Antonopoulos CN, Sfyroeras GS, Kakisis JD, et al. The role of soluble P selectin in the diagnosis of venous thromboembolism[J]. Thromb Res, 2014,133(1):17-24. DOI: 10.1016/j.thromres.2013.08.014. doi: 10.1016/j.thromres.2013.08.014 pmid: 24012101
[17]	Mauracher LM, Posch F, Martinod K, et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients[J]. J Thromb Haemost, 2018,16(3):508-518. DOI: 10.1111/jth.13951. doi: 10.1111/jth.13951 pmid: 29325226
[18]	Demers M, Wagner DD. Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression[J]. Oncoimmunology, 2013,2(2):e22946. DOI: 10.4161/onci.22946. doi: 10.4161/onci.22946 pmid: 23526174
[19]	Zhou X, Teegala S, Huen A, et al. Incidence and risk factors of venous thromboembolic events in lymphoma[J]. Am J Med, 2010,123(10):935-941. DOI: 10.1016/j.amjmed.2010.05.021. doi: 10.1016/j.amjmed.2010.05.021 pmid: 20920696
[20]	Abdel-Razeq H, Mansour A, Abdulelah H, et al. Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look![J]. Thromb J, 2018,16:2. DOI: 10.1186/s12959-018-0161-9. doi: 10.1186/s12959-018-0161-9 pmid: 29507532
[21]	Riondino S, Ferroni P, Zanzotto FM, et al. Predicting VTE in cancer patients: candidate biomarkers and risk assessment models[J]. Cancers (Basel), 2019, 11(1). pii: E95. DOI: 10.3390/cancers11010095.
[22]	Mcalister RK, Ito S. Minimal prolongation of prothrombin time with extended exposure to argatroban[J]. Pharmacotherapy, 2015,35(7):e122-e126. DOI: 10.1002/phar.1613. doi: 10.1002/phar.1613 pmid: 26147471
[23]	Fan S, Zhao G, An G. High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer[J]. J Int Med Res, 2019,47(1):215-224. DOI: 10.1177/0300060518799869. doi: 10.1177/0300060518799869 pmid: 30270808
[24]	Malaguarnera M, Latteri S, Bertino G, et al. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis[J]. Clin Exp Gastroenterol, 2018,11:373-380. DOI: 10.2147/CEG.S172663. doi: 10.2147/CEG.S172663 pmid: 30323642
[25]	Liang Y, He D, Wu L, et al. Elevated preoperative plasma D-dimer dose not adversely affect survival of gastric cancer after gastrectomy with curative intent: a propensity score analysis[J]. Chin J Cancer Res, 2018,30(2):254-262. DOI: 10.21147/j.issn.1000-9604.2018.02.08. doi: 10.21147/j.issn.1000-9604.2018.02.08 pmid: 29861610
[26]	Lee S, Huh SJ, Oh SY, et al. Clinical significance of coagulation factors in operable colorectal cancer[J]. Oncol Lett, 2017,13(6):4669-4674. DOI: 10.3892/ol.2017.6058. doi: 10.3892/ol.2017.6058 pmid: 28599468
[27]	Cao J, Fu Z, Gao L, et al. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma[J]. World J Surg Oncol, 2017,15(1):48. DOI: 10.1186/s12957-017-1104-9. doi: 10.1186/s12957-017-1104-9 pmid: 28219450
[28]	Feng JF, Yang X, Chen S, et al. Prognostic value of plasma d-dimer in patients with resectable esophageal squamous cell carcinoma in China[J]. J Cancer, 2016,7(12):1663-1667. DOI: 10.7150/jca.15216. doi: 10.7150/jca.15216 pmid: 27698903
[29]	Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer[J]. Br J Cancer, 2002,86(3):389-395. DOI: 10.1038/sj.bjc.6600069. doi: 10.1038/sj.bjc.6600069 pmid: 11875705
[30]	Liu B, Li B, Zhou P, et al. Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL)[J]. Clin Chim Acta, 2018,482:191-198. DOI: 10.1016/j.cca.2018.04.013. doi: 10.1016/j.cca.2018.04.013 pmid: 29649456
[31]	Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma[J]. Thromb Res, 2010,126(6):477-480. DOI: 10.1016/j.thromres.2010.08.017. doi: 10.1016/j.thromres.2010.08.017 pmid: 21126629
[32]	Diao D, Cheng Y, Song Y, et al. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer[J]. BMC Cancer, 2017,17(1):56. DOI: 10.1186/s12885-016-3043-1. doi: 10.1186/s12885-016-3043-1 pmid: 28086824
[33]	Berger MD, Heini AD, Seipel K, et al. Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia[J]. Hematol Oncol, 2017,35(4):789-796. DOI: 10.1002/hon.2307. doi: 10.1002/hon.2307 pmid: 27301773
[34]	Elmoamly S, Afif A. Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?[J]. Hematology, 2018,23(2):89-95. DOI: 10.1080/10245332.2017.1365458. doi: 10.1080/10245332.2017.1365458 pmid: 28823228